1,087 results match your criteria: "Pityriasis Rubra Pilaris"
Clin Exp Dermatol
February 2022
Department of Dermatology, Medical University of Warsaw, Warsaw, Poland.
There is a paucity of data concerning the usefulness of trichoscopy in patients with erythroderma. The aim of the study was to compare the trichoscopic features in erythroderma of various aetiologies. In total, 49 patients with a determined cause of erythroderma [including atopic dermatitis (AD), mycosis fungoides (MF), allergic contact eczema (ACE), psoriasis (Pso), Sézary syndrome (SS), drug reaction, pityriasis rubra pilaris (PRP), dermatomyositis (DM), actinic reticuloid (AR), crusted scabies (CS) and pemphigus foliaceus (PF)] were included in the study.
View Article and Find Full Text PDFClin Exp Dermatol
January 2022
Department of Dermatology, Solihull Hospital, University Hospitals Birmingham Foundation NHS Trust, Birmingham, UK.
We describe a case of a pityriasis rubra pilaris (PRP)-like eruption occurring following administration of the Pfizer-Biontech mRNA COVID-19 vaccine, with worsening of the condition following the second dose. To our knowledge, this is the first reported case of a PRP-like eruption as a cutaneous adverse event of the Pfizer-Biontech mRNA COVID-19 vaccine.
View Article and Find Full Text PDFJ Cutan Pathol
February 2022
University of California San Francisco, San Francisco, California, USA.
Background: Elevated epidermal interleukin (IL)-36 expression distinguishes psoriasis from eczematous dermatitis, but other psoriasiform dermatitides (PDs) have not been thoroughly investigated for IL-36 expression. In this study, we assess the IL-36 staining pattern (IL36-SP) in psoriasis variants and other PDs including lichen simplex chronicus (LSC), prurigo nodularis (PN), lichen planus (LP), tinea, pityriasis rubra pilaris (PRP), mycosis fungoides (MF), pemphigus foliaceus (PF), acute generalized exanthematous pustulosis (AGEP), impetigo (IMP), and syphilis (SY).
Methods: IL-36 immunostaining was performed on 307 cases of psoriasis and various PDs.
J Eur Acad Dermatol Venereol
December 2021
Dermatology Department, Hospital Universitario de la Princesa, Madrid, Spain.
J Invest Dermatol
January 2022
Department of Dermatology, Oregon Health & Science University, Portland, Oregon, USA. Electronic address:
Arch Dermatol Res
August 2022
Department of Dermatology, Stony Brook University Hospital, Stony Brook, NY, USA.
Ustekinumab is approved for the treatment of psoriasis and Crohn's disease. Because many dermatological conditions are due to immune-mediated development, ustekinumab may be effective in other conditions. A systematic review of the off-label uses of ustekinumab, as well as on-label adverse effect, was performed, reporting on clinical improvement.
View Article and Find Full Text PDFActas Dermosifiliogr (Engl Ed)
June 2021
Servicio de Dermatología, Consorci Corporació Sanitària Parc Taulí, Universidad Autónoma de Barcelona, Spain.
Autoinflammatory keratinization disease (AiKD) is a novel clinical concept encompassing diseases with a genetic background and mixed pathogenic mechanisms of autoinflammation and autoimmunity, leading to an aberrant keratinization of the skin. Recent advances in medical genetics have revealed genetic causes and/or predisposing factors for a number of AiKD's, such as mutations in IL36RN related with pustular psoriasis, acrodermatitis continua and hidradenitis suppurativa, in CARD14 in pityriasis rubra pilaris type V and some forms of pustular psoriasis, and in NLRP1 related with familial keratosis lichenoides chronica (KLC). It is suspected that AiKD pathophysiology would also be involved in non-monogenic disorders.
View Article and Find Full Text PDFClin Exp Dermatol
December 2021
Dermatology Unit, University of Campania, Luigi Vanvitelli, Naples, Italy.
Pediatr Dermatol
July 2021
Paediatrics Academic Clinical Programme, SingHealth Duke-NUS Graduate Medical School, Singapore, Singapore.
CARD14-associated papulosquamous eruption (CAPE) is a rare autosomal dominant dermatosis that presents classically in early childhood with clinical features of both psoriasis and pityriasis rubra pilaris (PRP). The disease is known to be refractory to topical and systemic therapies classically used for psoriasis, with the majority of reported cases requiring treatment with biologics, such as ustekinumab and secukinumab. We present a toddler with a clinical presentation consistent with CAPE and found to have a novel heterozygous variant of the CARD14 gene.
View Article and Find Full Text PDFJ Eur Acad Dermatol Venereol
October 2021
Department of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland.
Actas Dermosifiliogr (Engl Ed)
May 2021
Departamento de Dermatología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. Electronic address:
JAAD Case Rep
June 2021
Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan.
Australas J Dermatol
August 2021
University of Melbourne, Parkville, Victoria, Australia.
Am J Hum Genet
June 2021
Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido 060-8638, Japan; Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan. Electronic address:
Revertant mosaicism, or "natural gene therapy," refers to the spontaneous in vivo reversion of an inherited mutation in a somatic cell. Only approximately 50 human genetic disorders exhibit revertant mosaicism, implicating a distinctive role played by mutant proteins in somatic correction of a pathogenic germline mutation. However, the process by which mutant proteins induce somatic genetic reversion in these diseases remains unknown.
View Article and Find Full Text PDFActas Dermosifiliogr
July 2022
Servicio de Dermatología, Hospital do Meixoeiro, EOXI, Vigo, Pontevedra, España.
J Dtsch Dermatol Ges
August 2021
Department of Dermatology, Venereology, and Allergology, University Medical Center, Göttingen, Germany.
Int J Womens Dermatol
March 2021
Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston, SC, United States.
Clin Exp Dermatol
October 2021
Department of Dermatology, Geneva University Hospital, Geneva, Switzerland.
Colomb Med (Cali)
March 2021
Universidad San Ignacio de Loyola, Lima, Perú. Universidad San Ignacio de Loyola Universidad San Ignacio de Loyola Lima Peru.
J Am Acad Dermatol
May 2022
Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Int J Dermatol
August 2021
The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Hautarzt
January 2022
Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland.
Long-term methotrexate (MTX) treatment is known to cause MTX-associated lymphoproliferative disorder (MTX-LPD). A 58-year-old woman with psoriasis vulgaris and pityriasis rubra pilaris was treated with a combination of MTX and ustekinumab for 4 months when she developed generalized lymphadenopathy. The initial histopathological analysis indicated Hodgkin's lymphoma; however, assessing the patient's clinical history revealed the diagnosis of MTX-LPD.
View Article and Find Full Text PDFJ Am Acad Dermatol
April 2022
Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address:
Br J Dermatol
July 2021
Dermatology Department, Hospital de Santo António dos Capuchos, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal.